We’re proud to return as a sponsor of the ALS/MND Symposium this weekend! Visit Booth #13 to learn how #NULISA is transforming early disease detection and biomarker discovery for neurologic disorders like #ALS and #MND. 👉 Learn more: https://t.co/n2SHMvboXT #ALSMND2025

🧭 Don’t miss our sponsored talk at #BSI25! Rym Abida, MD, UCL presents: “Can we predict sustained remission in SLE?” 💡 Discover how fluid biomarkers track disease & guide therapy. 📆 Thu 04 Dec | 🕐 13:00 | 📍 Exhibition Hall 2 #FluidBiomarkers #Lupus #PrecisionImmunology

🔬 Big day for proteomics coming up on 9 Dec! We’re co-hosting an online event with 12 expert speakers diving into the future of biomarker discovery. Open to everyone — register & tune in https://t.co/KUHywEp2vq

We’re at #BSI25 in Liverpool. Immunology is front and centre, and we’re showing how Alamar’s #fluidbiomarker tech helps researchers decode immune activity, therapy response and tumour–immune interactions and don’t miss our UCL collaborator presenting on Thursday!

#HUPO2025 Day 3 Poster highlight: “Comprehensive Cross-Platform Evaluation of Eight Plasma Proteomics Technologies Using a Single Cohort” presented by Sara Ahadi, Alkahest Final day — let’s make it count! #Proteomics #NULISA #ARGOHT #HighThroughput #FluidBiomarkers

🧭 Don’t miss our Industry Lunch Seminar at #HUPO2025! 🗓 Tuesday, November 11 | 12:15 – 1:15 pm 📍 Harbour C (Lunch Provided) “Beyond Neurofilament: ALS Plasma Biomarkers” - Eleanor Thomas, MD, PhD Emory University) #Proteomics #ALS #Neurology #PrecisionProteomics

🔬 HUPO 2025 Day 3 Oral Poster Alert: “Plasma Proteomic Signatures Predict Progression-Free Survival in NSCLC Patients Undergoing Anti-PD-L1 and Chemotherapy” presented by Yuehan Feng, Biognosys. #HUPO2025 #Proteomics #Oncology #Immunotherapy #NSCLC #NULISA #ARGOHT

#HUPO2025 Day 2 highlight: Poster PV.01.048 “Using Proteomics in Mendelian Randomization and Randomized Controlled Trial Settings to Understand the Aetiology of Multiple Myeloma” presented by Lucy Goudswaard, University of Bristol #Proteomics #MultipleMyeloma #NULISA #ARGOHT

❄️ It’s a snowy start to #HUPO2025 here in Toronto, but things are heating up at Booth #401! Discover how our NULISA™ platform and ARGO™ HT system are redefining ultra-sensitive proteomics. #HUPO2025 #Proteomics #NULISA #ARGOHT #PrecisionProteomics #LifeScienceInnovation

🔬 Keynote Alert! We’re thrilled to have Hanno Steen, PhD (Harvard Medical School) give the keynote on NULISA, a next-generation platform redefining the limits of proteomic sensitivity, during Advances in Proteomics & Metabolomics 2025. 👉 Register now: https://t.co/gz7k4kQYbb

🚀 Leadership Momentum at Alamar Biosciences We’re thrilled to welcome Justin McAnear as CFO and celebrate Tod White’s promotion to President. Together, they’ll help drive our next chapter of growth in precision proteomics. https://t.co/F6uKRajcHt #Proteomics #NULISA #biomarkers

🚀Just Launched: NULISAqpcr™ BD-pTau217 Assay! A game-changer in Alzheimer’s research—our new blood-based assay delivers unmatched sensitivity and CNS specificity for detecting brain-derived pTau217. Learn more: https://t.co/5qpco6oGhb Read the release: https://t.co/ztoXeJIlhx

We’re heading to Qatar for #QPC2025 and excited to connect with scientists and technologists driving advances in #proteomics and #biomarker discovery. Let’s talk assay sensitivity, multiplexing, and the future of low-abundance protein detection https://t.co/RQ8yHyoi7a #NULISA

At todays #BIOMUK2025 Dr. Maura Malpetti (Univ. Cambridge) shares how NULISA™ proteomics is uncovering fluid biomarkers (pTau, NfL, inflammation) across AD, FTD & PSP — reshaping how we study neurodegeneration & disease progression. #Biomarkers #Proteomics #Neurodegeneration

The biomarker community meets in London for #BIOMUK2025 (Sept 30–Oct 1). Fluid biomarkers are reshaping how we study neurodegeneration & disease progression — and new ultra-sensitive assays are helping researchers get there. #NULISA #Biomarkers #Proteomics

🧬 We’re excited to announce our collaboration with Human Longevity, Inc. to bring NULISAseq™ proteomic panels into Human Longevity’s precision health programs, advancing early detection and monitoring of inflammation & neurological health 👉 Read more: https://t.co/sjKuxyR41D

🧠 Fluid Biomarkers Beyond Alzheimer’s: Insights with Dr. Cheryl Wellington Episode 3 of The Biomarker Edge explores how fluid biomarkers are advancing Alzheimer’s research and opening new possibilities in TBI and stroke Watch the Full episode → https://t.co/rDVLb9qAER

We’re proud to announce that Dr. Xiao-Jun Ma has been recognized among the Top 25 Biotech & Life Sciences Executives of 2025 by The Healthcare Technology Report. His two decades of leadership continue to shape the future of proteomics innovation. 🎉 Read: https://t.co/MxjTcAB9fN

🚀 Unlock the Future of Protein Biomarkers – Oct 1, San Diego! Join Alamar Biosciences + KOLs from UCLA, Stanford & local biotechs as we share new data with #NULISA technology, advancing research in #neurodegeneration, #inflammation & more. 👉Register: https://t.co/8Dalz1H0XY

Join us Wed, Aug 20 @ 12:30 CEST (Room 1.34) for a Lunch & Learn on attomolar‑sensitive profiling of inflammatory proteins.🍽 Lunch is on us! Speakers: Prof. Cezmi Akdis & Feng HeFeng 👉 https://t.co/9kEDDGA4tR #IUIS2025 #Proteomics #Immunology #LunchAndLearn